Bridge to Life Ltd. Receives Breakthrough Device Designation from the FDA
Bridge to Life advances their perfusion system development with the breakthrough device designation for the LifeCradle® Heart Preservation Transport system.
Bridge to Life Ltd. Announces First Enrollment and Orthotopic Liver Transplantation in its Pivotal Bridge to HOPE Liver Clinical Trial
Bridge to Life Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced first enrollment and orthotopic liver transplantation in its U.S. [...]
Bridge to Life Ltd. Receives Investigational Device Exemption Approval from the FDA
Bridge to Life looks to begin patient enrollment in their Bridge to HOPE Liver Clinical Trial utilizing their VitaSmart™ Liver Machine Perfusion System by the end of 2021. NORTHBROOK, Ill., Dec. [...]
Bridge to Life Announces First Close of $56 Million Growth Financing Led by Perceptive Advisors
Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the first closing of a growth financing, totaling $56 million, led by [...]
Bridge to Life CEO Stevan Schweighardt Featured in CEOCFO Magazine
Bridge to Life Chairman & CEO Stevan Schweighardt was interviewed in a feature piece for CEOCFO Magazine. He discusses the challenges of the transplant field and Bridge to Life's current and [...]
Bridge to Life and Tevosol Merge to Commercialize Portable Normothermic Machine Preservation Technology Platform for Organ Transplantation
Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, and Tevosol, Inc., a clinical stage medical device startup, today announced their [...]
